StockTwits, founded in 2008 by Howard Lindzon and Soren Macbeth, is a leading social media platform designed specifically for investors and traders to share real-time market insights, ideas, and strategies. Headquartered in New York City, the company pioneered the use of "cashtags" (e.g., $AAPL) to organize financial discussions, initially integrating with Twitter before evolving into a standalone network.
Bank Nifty slipped on Tuesday, led by weakness in private sector banks. Orchid Research saw short-term bearishness but maintained a "buy on dips" view for positional traders.
Summers said China didn't make any consequential or significant change in its policies and that it was the U.S. that made a retreat from its extreme tariff policy.
Orchid Research has identified strong buying interest in Kalyan Jewellers, particularly at the ₹550 strike price, with expectations of an intraday surge if the stock surpasses this level.
Indian defense stocks rallied sharply today, with BEL emerging as the top contributor to the Nifty 50. Orchid Research flagged a breakout with strong volumes and momentum, setting a near-term target of ₹365.
CEO Andy Marsh said there is strong support for hydrogen production hubs in Republican-ruled states, and the projects would not be viable without the tax credits.
LTIMindtree gained after bagging a $450-million AI-led contract, its biggest ever, sparking optimism about future growth. Technical analyst Priyank Sharma noted a bullish setup forming, with ₹4,483 acting as a key support.
Tata Steel’s March quarter earnings show steady improvement in revenue and profits. Technical analysts see bullish momentum with possible breakout above key resistance levels.
The company’s shares are attempting a technical recovery, but SEBI-registered analyst Lalit Mundhra says a close above ₹1,031 is crucial to trigger fresh buying. He sees strong support near ₹910–₹915.
The company’s shares have gained positive momentum after closing above their 200-day moving average for three consecutive days, with SEBI-registered analyst Kush Ghodasara recommending buying with a stop loss at ₹3,420.
The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.
Tariff news flow, first-tier economic data, and a few earnings reports could decide the day's trading direction, although the momentum is decisively in favor of further gains.
Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options.
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting its near-term impact on pharma stocks.
Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.
CEO Larry Coben said the transaction is financially compelling as it strengthens the company’s credit profile, boosts its growth rate, and supports continued robust capital returns.
KindlyMD CEO Tim Pickett said the merger allows the company to preserve and expand its mission to combat opioid dependency through alternative medicine while gaining a new engine for shareholder value creation.
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries.
U.S. Treasury Secretary Scott Bessent cited the need to protect the semiconductor, steel, and pharmaceutical industries in the negotiations between the two countries.
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.
A ceasefire between India and Pakistan and a breakthrough U.S.-China trade deal sparked a major rally on Dalal Street; IT, metals, and travel stocks led the surge amid broad-based buying.
Analyst Saurabh Sahu believes the stock has the potential to rise to the ₹830 to ₹850 range, while recommending a strict stop-loss at ₹775 to manage the downside risk.
The firm's report echoes the sentiment across the travel and hospitality sector, where demand is strained due to macroeconomic uncertainties and geopolitical unrest.
The Boston-based firm forecasted 2025 adjusted EBITDA between $540 million and $560 million, compared with its earlier projection between $510 million and $530 million.
The railroad operator said the agreement includes general wage increases and health and welfare improvements, similar to its agreements with 13 other unions.
This would mean the combined 145% tariffs on Chinese imports will be reduced to 10% by May 14, while the 20% duties related to fentanyl will stay in place.
Trump’s Most Favored Nation (MFN) drug pricing policy could significantly compress margins, disrupt product pipelines, and force Indian firms to rework their U.S. strategies.
